NASDAQ:CMPS
Compass Pathways PLC Stock News
$5.96
+0.0100 (+0.168%)
At Close: Jul 02, 2024
Compass Pathways appoints Lori Englebert as Chief Commercial Officer
06:30am, Wednesday, 26'th Jun 2024
LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, t
Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
04:01pm, Monday, 24'th Jun 2024
LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
Should You Buy the Dip on Compass Pathways Stock?
06:25am, Wednesday, 12'th Jun 2024
Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators.
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
12:15pm, Thursday, 23'rd May 2024
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through
These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring
08:05am, Tuesday, 21'st May 2024
Compass Pathways will report some key data in Q4. One of its competitors will soon face a critical interaction with regulators.
COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript
05:31pm, Saturday, 11'th May 2024
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2024 Results Conference Call May 8, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxa
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
06:45am, Wednesday, 08'th May 2024
LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental he
LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, to
Compass Pathways to announce first quarter financial results on May 8, 2024
04:58pm, Friday, 03'rd May 2024
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental he
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
04:01pm, Monday, 01'st Apr 2024
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announce
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
08:00am, Thursday, 28'th Mar 2024
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a Ne
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
09:30am, Tuesday, 05'th Mar 2024
Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.
COMPASS Pathways plc (CMPS) Q4 2023 Earnings Call Transcript
11:43am, Thursday, 29'th Feb 2024
COMPASS Pathways plc (CMPS) Q4 2023 Earnings Call Transcript
